Clene Inc. (CLNN) · Oct 19, 2026 · Other events

Clene NDA filing puts CNM-Au8 into FDA review for ALS

NDA submitted — Filed in October, ahead of the company’s early-Q4 plan

Clene’s ALS NDA for CNM-Au8 is filed, advancing the accelerated-approval path—but FDA acceptance and confirmatory Phase 3 work remain ahead.

Clene is a late clinical-stage biotech whose lead value driver is CNM-Au8, an ALS therapy being advanced through an accelerated-approval route built around neurofilament light-chain biomarker data; the FDA previously said the proposed data may support an NDA, while Clene had most recently targeted an early-fourth-quarter 2026 filing.

The regulatory milestone is now real, not merely planned. Clene says it submitted the NDA earlier in October for accelerated approval of CNM-Au8 in ALS. That moves the program from FDA-preparation mode into formal agency review, but the filing does not say the FDA has accepted the application, assigned a review clock, or agreed that approval is warranted.

Versus expectations, this is confirmation rather than a surprise. The submission had already been telegraphed for the third quarter and then early fourth quarter of 2026, so the main incremental information is that Clene completed the filing on schedule—apparently earlier in October—not that the company changed its regulatory strategy.

The central business risk has shifted from filing execution to FDA validation. Clene still needs the agency to accept and review the NDA, decide whether the biomarker evidence supports accelerated approval, and ultimately require the planned confirmatory Phase 3 RESTORE-ALS study. The company says preparations for that study are continuing. 〔0〕

Bottom line: This advances Clene’s most important program into the FDA-review phase, but it is largely an expected milestone rather than a changed clinical verdict. The next meaningful inflection is FDA acceptance and the resulting review timeline, not the submission itself.

What to watch next

FDA acceptance decision and PDUFA date

Original filing on SEC EDGAR

More Clene Inc. news

Clene NDA filing puts CNM-Au8 into FDA review for ALS | CLNN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.